

1 **SARS-CoV-2 variants in Paraguay: Detection and surveillance with a readily modifiable,**
2 **multiplex real-time RT-PCR**

3
4 Magaly Martinez^{1,*} and Phuong-Vi Nguyen^{2,*}, Maxwell Su², Fátima Cardozo³, Adriana
5 Valenzuela³, Laura Franco¹, María Eugenia Galeano¹, Leticia Elizabeth Rojas¹, Chyntia Carolina
6 Díaz Acosta¹, Jonás Fernández¹, Joel Ortiz¹, Florencia del Puerto⁴, Laura Mendoza³, Eva Nara¹,
7 Alejandra Rojas^{5,†,#} and Jesse J. Waggoner^{2,6,†,#}

8
9 ¹ Universidad Nacional de Asunción, Instituto de Investigaciones en Ciencias de la Salud,
10 Departamento de Biología molecular y Biotecnología, Paraguay

11 ² Emory University, Department of Medicine, Division of Infectious Diseases, Atlanta, Georgia,
12 USA

13 ³ Universidad Nacional de Asunción, Instituto de Investigaciones en Ciencias de la Salud,
14 Departamento de Salud Pública, Paraguay

15 ⁴ Universidad Nacional de Asunción, Instituto de Investigaciones en Ciencias de la Salud,
16 Departamento de Medicina Tropical, Paraguay

17 ⁵ Universidad Nacional de Asunción, Instituto de Investigaciones en Ciencias de la Salud,
18 Departamento de Producción, Paraguay

19 ⁶ Rollins School of Public Health, Department of Global Health, Atlanta, Georgia, USA

20
21 * These first authors contributed equally

22 † These last authors contributed equally

23 # Corresponding Authors: Alejandra Rojas, IICS-UNA, Departamento de Producción, Dr. Cecilio
24 Báez y Dr. Villamayor, Campus Universitario, San Lorenzo, Paraguay, 2160; telephone:
25 +59598.2414456; email, arojass@iics.una.py. Jesse J. Waggoner, 1760 Haygood Drive NE,
26 Room E-169, Bay E-1, Atlanta, GA, USA, 30329; telephone: +1.404.712.2360; email,
27 jjwaggo@emory.edu

28 **Abstract**

29 *Objectives*

30 The objective of the current study was to develop a lower-cost and scalable protocol to identify
31 and monitor SARS-CoV-2 variants in Paraguay by pairing real-time RT-PCR detection of spike
32 mutations with amplicon Sanger sequencing and whole-genome Nanopore sequencing.

33

34 *Methods*

35 201 acute-phase nasopharyngeal samples from SARS-CoV-2-positive individuals were tested
36 with two rRT-PCRs: 1) N2RP assay to confirm SARS-CoV-2 RNA detection (CDC N2 target),
37 and 2) the Spike SNP assay to detect mutations in the *spike* receptor binding domain. The assay
38 was performed with probes to identify mutations associated with the following variants: alpha
39 (501Y), beta/gamma (417variant/484K/501Y), delta (452R/478K), and lambda (452Q/490S).

40

41 *Results*

42 All samples were positive for SARS-CoV-2 in the N2RP assay (mean Ct, 20.8; SD 5.6); 198/201
43 (98.5%) tested positive in the Spike SNP assay. The most common genotype was
44 417variant/484K/501Y, detected in 102/198 samples (51.5%) and most consistent with P.1
45 lineage (gamma variant) in Paraguay. No mutations (K417 only) were found in 64/198 (32.3%);
46 and K417/484K was identified in 22/198 (11.1%), consistent with P.2 (zeta). Seven samples
47 (3.5%) tested positive for 452R without 478K, and one sample with genotype K417/501Y was
48 confirmed as B.1.1.7 (alpha). Results were confirmed by Sanger sequencing in 181/181 samples
49 (100%) with high-quality amplicon sequences, and variant calls were consistent with Nanopore
50 sequencing in 29/29 samples.

51

52 *Conclusions*

53 The Spike SNP assay provides accurate detection of mutations associated with SARS-CoV-2
54 variants. This can be implemented in laboratories performing rRT-PCR to improve population-
55 level surveillance for these mutations and inform the judicious use of scarce sequencing
56 resources.

57 **Introduction**

58 Amidst the global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-
59 CoV-2) numerous variants have emerged due to mutations in the positive-sense RNA genome.
60 Variants of concern (VOCs) and variants of interest (VOIs) bear mutations that impact detection,
61 treatment, clinical severity, transmission, and/or immune protection from prior infection or
62 vaccination [1]. Whole genome sequencing is the reference method for detecting and tracking
63 variants, but this is a time- and resource-intensive process with capacity varying markedly
64 between regions [2-5]. It has been estimated that 5% of all samples need to be sequenced to
65 reliably detect variants at a prevalence of 0.1-1% [3], yet for many regions, this goal remains
66 unattainable. Limited available sequencing capacity and overwhelming case numbers have
67 motivated the development of real-time reverse transcriptase PCRs (rRT-PCRs) for the detection
68 and surveillance of specific mutations found among VOCs/VOIs [6-20]. For these reasons, our
69 group designed the Spike SNP assay, which is multiplex a rRT-PCR designed to detect specific
70 mutations in the receptor binding motif of the Spike receptor binding domain (RBD) (Figure 1)
71 [20].

72
73 In Paraguay, the first confirmed SARS-CoV-2 infection was reported on 07 March 2020 [21]. As
74 of 25 August 2021, 457,971 cases were reported in the country with 228 whole genome
75 sequences (0.05% of cases) available in the GISAID database (www.gisaid.org) [22]. Published
76 reports on case series in Paraguay have been limited to descriptive analyses of symptoms and
77 disease outcomes [23, 24]. As such, little is known about variants that circulated in the country
78 during the beginning of the pandemic in 2020. However, data from 2021 show that variants
79 originally detected in Brazil, such as the P.1 (gamma variant) and P.2 (zeta) lineages have

80 circulated widely (GISAID database). Nanopore sequencing on the portable MinION sequencer
81 has recently become available in Asunción, the capital of Paraguay, to detect and monitor SARS-
82 CoV-2 variants for the first time, and this technology provides lower cost and more rapid whole
83 genome sequencing compared to other methods [2, 25]. The objective of the current study was to
84 develop an economical and scalable protocol based on the Spike SNP assay and Nanopore
85 sequencing to identify and monitor VOCs/VOIs in acute-phase samples in Paraguay.

86

87 **Methods**

88 **Clinical samples**

89 Nasopharyngeal (NP) samples were obtained from residual baseline surveillance samples at the
90 Instituto de Investigaciones en Ciencias de la Salud, Universidad Nacional de Asunción (IICS-
91 UNA) Laboratory. Samples were deidentified, aliquoted and stored at -80°C until nucleic acid
92 extraction. A convenience set of 201 SARS-CoV-2 positive samples was chosen for this study.
93 Samples tested positive for the envelope gene target of the Charité protocol [26] with a cycle
94 threshold (Ct) <34 and were collected from different cities in Paraguay from symptomatic and
95 asymptomatic individuals. This study was reviewed and approved by the IICS Scientific and
96 Ethics Committee (P38/2020) and the Emory Institutional Review Board (study 00110736).

97

98 **Spike SNP design and performance**

99 Hydrolysis probes were designed to detect mutations associated with emerging variants of
100 concern: L452Q (CAG>CTG) and F490S (UUU>UCU, C.37, lambda), E484Q (GAA>CAA,
101 B.1.617.1, kappa), and T478K (ACA>AAA, B.1.617.2, delta). All new probes were designed as
102 described [20], without locked nucleic acids (LNA). Unmodified probes for 484K and 501Y

103 were also designed and evaluated. New probes were individually evaluated using SARS-CoV-2
104 genomic RNA in singleplex assays. Probes that provided the most sensitive signal based on Ct
105 value, with preserved specificity, were selected. Subsequently, probes were tested in
106 combination and compared side-by-side with the corresponding singleplex assays. Probe
107 evaluations were performed utilizing characterized variant control samples kindly provided by
108 the National Institutes of Health Variant Task Force.

109

110 Nucleic acids were extracted from all samples on an EMAG instrument (bioMérieux, Durham,
111 NC) from 200 μ L of NP swab and eluted in 50 μ L. All rRT-PCRs were performed on a Rotor-
112 Gene Q instrument (Qiagen, Germantown, MD) using 20 μ L reactions of the Luna Probe One-
113 Step RT-qPCR Kit (New England Biolabs, Ipswich, MA) and 5 μ L of nucleic acid eluate. Each
114 sample was tested in a duplex reaction for the SARS-CoV-2 nucleocapsid 2 target and RNase P
115 (N2RP) as well as two different reactions of the Spike SNP assay including probes for 1) K417,
116 452R, 484K, and 501Y, as described [20]; and 2) 452Q, 490S, and 484Q. During the study, the
117 478K probe became available, and all samples with 452R were tested with this probe to evaluate
118 for the delta variant. The N2RP assay was performed as described [20, 27]. For full Spike SNP
119 methods, please see supplemental material.

120

121 **Sequencing**

122 All rRT-PCR products from the first Spike SNP reaction (348-base-pair amplicon) were stored at
123 4°C and later shipped to GeneWiz (South Plainfield, NJ) for Sanger sequencing. Amplicon
124 sequence was considered to be high quality and included for analysis if it achieved a quality
125 score \geq 40 and had base calls for all probe targets in at least one direction. A quality score \geq 40,

126 as defined by the company, signifies a mean probability of error $\leq 0.01\%$ for each base call
127 across the amplicon.

128

129 Complete genome sequencing was performed following the ARTIC Network protocol using the V3
130 primers scheme [28]. The genomic libraries were prepared and then loaded on a R9.4.1 flow cell
131 (ONT FLO-MIN106) for sequencing with MinION device (MIN-101B). Basecalling,
132 demultiplexing and trimming was carried out by Guppy toolkit integrated in the MinKNOW
133 Nanopore software (Oxford Nanopore Technologies, UK). Genome assembly and consensus
134 sequences were obtained with Nanopore EPI2ME (using Flye and Medaka respectively). The
135 Nextclade tool was used for clade definition and mutation calling [29] and lineages were
136 assigned using Pangolin web server [30]. Sequences were deposited in the GISAID database
137 with accession numbers provided in Table 3.

138

139 **Statistics**

140 Basic statistical analyses were performed using GraphPad Prism version 9.0.2 (GraphPad
141 Software, San Diego, CA).

142

143 **Results**

144 *Spike SNP optimization*

145 For initial testing, a Spike SNP assay was developed that contained probes for 452Q, 484Q, and
146 490S. With the global emergence of the B.1.617.2 and lack of 484Q detection, the 478K probe
147 was incorporated in the assay in place of 484Q. Addition of the 478K probe had no impact on
148 452Q or 490S detection (Figure 2), and despite overlapping sequences, the 478K and 484Q

149 probes demonstrated no interference when combined in the same reaction (Figure S1). New
150 probes for 484K and 501Y without LNA bases provided sensitive detection at both sites, though
151 Ct values with the unmodified 484K probe were ~2 cycles later than those generated with the
152 LNA probe (Figure S2). Testing of clinical samples in the current study was performed with the
153 original 484K and 501Y probes to maintain consistency with existing protocols. All primers and
154 probes used in or developed for this study are shown in Table 1, and their respective locations
155 across the amplicon are displayed in Figure 1.

156

157 *SNP detection in clinical samples*

158 Clinical samples were collected between November 2020 and April 2021. 113 participants were
159 female (56.8%, of 199 with gender available), and age and day of symptoms at sample collection
160 are shown in Table 2 along with N2RP and Spike SNP assay results. The distribution of N2
161 target Ct values is shown in Figure 3. The most common genotype identified was
162 417variant/484K/501Y (102/198 samples, 51.5%), which is consistent with B.1.351 (beta) and
163 P.1. Large numbers of cases were also detected with signal for K417 only (64/198, 32.3%),
164 consistent with a non-variant/ancestral lineage, and K417/484K (22/198, 11.1%), which is
165 observed in P.2 (zeta), among others. Seven samples (3.5%) had the genotype K417/452R but
166 tested negative with the 478K probe and were thus not consistent with B.1.617.2. Samples with
167 the 417variant/484K/501Y genotype had significantly lower N2 Ct values (mean 19.3, standard
168 deviation 5.0) than all other samples (22.0, 5.4; $p < 0.001$, data not shown) and samples with
169 K417 only (22.1, 5.4; $p = 0.002$; Figure 3B). No differences in patient age or day of symptoms
170 were observed based on genotype ($p > 0.05$ for all comparisons).

171

172 *Amplicon and whole genome sequencing*

173 High quality amplicon sequences were obtained from 181 samples (181/201, 90.0%) by Sanger
174 sequencing, and results confirmed Spike SNP genotype calls for all samples (Table 2).

175 Characteristic findings for samples with 484K, with and without 501Y, are shown (Figure 4). All
176 samples with variant calls at position 417 had the mutation AAG>ACG conferring K417T
177 observed in P.1. One sample had 484K detected in the Spike SNP assay (genotype K417/484K)
178 but E484 based on the consensus Sanger sequence. On review of the tracing, there was a mixture
179 of G and A bases at the first position of codon 484, consistent with evidence of a mixed viral
180 population in this sample. Notably, this sample had a late Ct value for 484K (38.4) relative to
181 K417 (34.3) when compared to other samples with this genotype (mean Ct difference 0.4,
182 standard deviation 0.2). In addition to mutations targeted in the Spike SNP assay, 4 samples
183 (2.2%) had a mutation conferring T478R (ACA>AGA), and one sample (0.5%) had a mutation
184 resulting in N501T (AAU>ACU).

185
186 Whole genome sequences for 29 samples were obtained using ARTIC protocol. Ten different
187 lineages were identified (Table 3) [30]. Nanopore sequencing confirmed Spike SNP genotype
188 calls for all samples. Samples bearing genotype 417variant/484K/501Y belonged to the P.1
189 lineage and P.1.2 sub-lineage. Genotype of only K417 was found in samples of lineages
190 B.1.1.28, B.1.1.33, B.1.1.277 and N3 all within 20B Nextstrain clade and lineage B.1.499 (clade
191 20C) [29]. The P.2 lineage that also belongs to 20B clade showed the K417/484K genotype. One
192 sample with genotype K417/501Y was classified as B.1.1.7 (alpha). A lineage from 2020 that
193 was still circulating during 2021, A.2.5.2, was found in one sample with genotype K417/452R.

194

195 **Discussion**

196 Among individuals with SARS-CoV-2 infection in Paraguay, the Spike SNP assay provided
197 accurate detection of targeted mutations in the RBD and, in conjunction with the employed
198 sequencing protocols, confirmed the predominance of B.1.1.28, P.2 and P.1 in this population
199 between November 2020 and April 2021, as well as the relative absence of B.1.1.7. Given
200 frequent travel between Paraguay and Brazil, B.1.1.28 lineage was expected to account for a high
201 proportion of cases in late 2020 and early 2021, to be later replaced by P.1 and P.2. Samples with
202 P.1 had lower Ct values in our population. A similar finding was documented initially in Brazil
203 and likely results in increased transmissibility of gamma variant with replacement of other
204 lineages [31, 32]. P.1 and P.2 lineages were readily differentiated from one another in the Spike
205 SNP assay, and in a real-world scenario, N2RP and Spike SNP assays could be performed
206 sequentially to diagnose SARS-CoV-2 infection, identify a set of common mutations, and select
207 samples for downstream sequencing [4, 5, 20].

208
209 For the current study, new probes were generated for mutations that occur within the target
210 region and are associated with emerging VOCs/VOIs, including delta and lambda variants
211 (Figure 1). As new designs do not involve separate primer-probe sets, the assay can be readily
212 modified and reconfigured to include probes that match circulating variants in a particular
213 region. All new probes were designed without LNA bases yet demonstrated similar performance
214 to previous designs (Figure S1). Although LNA bases have proven important for detection of
215 K417 mutations, avoiding their use in other probes improves access to and reduces costs for
216 these oligos. An additional benefit to the current design is that up to 4 mutations are targeted in a
217 single reaction, which has been found to improve variant classification [9]. Other published rRT-

218 PCR protocols for the detection of a similar number of mutations generate 2 or more amplicons
219 in single-reaction [12, 15, 17] or multiple-reaction designs [6, 8, 14, 16], and such protocols may
220 be more difficult to modify in response to the emergence of new variants.

221
222 Sequencing methods employed as part of our testing protocol included whole genome
223 sequencing on a MinION device and Sanger sequencing of the Spike SNP amplicon. Nanopore
224 sequencing has become a common method worldwide and particularly in locations where use of
225 short-read sequencing platforms is less feasible. MinION sequencing has been well described for
226 SARS-CoV-2 and provides formal confirmation of detected variants, which cannot be achieved
227 by rRT-PCR alone [4, 5, 25, 31]. Amplicon sequencing provides less information, but as
228 demonstrated in this study, it serves to confirm Spike SNP calls, differentiate B.1.351 and P.1,
229 and identify additional mutations in the receptor binding motif. In our study, 4 individuals had
230 the T478R mutation; the whole genome of two of them were sequenced and were assigned the
231 B.1.499 lineage. This lineage circulated widely in Argentina during 2020, but the mutation
232 T478R was not reported. While this mutation is distinct from T478K found in the B.1.617.2
233 (delta), mutations at position 478 have developed in vitro and confer decreased antibody
234 neutralization, indicating that such mutations may benefit the virus through immune escape [33,
235 34]. Finally, one individual was identified with a possible mixed infection or a minor variant
236 bearing 484K [35, 36]. Such infections do not appear to cause more severe clinical disease [35],
237 but this case highlights one potential benefit of rRT-PCR surveillance if key mutations can be
238 detected that are not observed in the consensus sequence.

239

240 The degree of multiplexing possible in the Spike SNP assay is limited by the number of channels
241 available in common real-time PCR instruments (4-5) as well as the defined 348-base-pair target
242 region. Based on results of testing for 478K and 484Q in a single reaction, overlapping probes do
243 not impact performance (Figure S1). However, multiplexed detection of key mutations outside of
244 the Spike SNP target region would require additional primer-probe sets and assay optimization.
245 A limitation to the current study is the utilization of retrospective convenience samples to
246 evaluate the testing protocol. Although new data on SARS-CoV-2 variants in Paraguay were
247 generated, we cannot calculate variant prevalence from these data.

248

249 In conclusion, the Spike SNP assay provides accurate detection of mutations that are associated
250 with VOCs/VOIs in Paraguay. This can be implemented in SARS-CoV-2 testing protocols to
251 triage samples for whole genome sequencing in the MinION platform or direct amplicon
252 sequencing, which provides additional information. The assay can be implemented in any
253 laboratory performing rRT-PCR to improve surveillance for these mutations and inform the
254 judicious use of scarce sequencing resources.

255

256 **Acknowledgements**

257 The authors thank the staff at the Instituto de Investigaciones en Ciencias de la Salud,
258 Universidad Nacional de Asunción, and collaborating laboratories: Letizia Carpinelli
259 (CYRLAB), Fátima Ovando (Hospital de Clínicas, UNA), Graciela Riera (MeyerLab) and Stefan
260 Goertzen (Hospital Loma Plata) for their support during the study period and the COVID
261 pandemic in Paraguay. We also thank members of the Variant Task Force at Emory University,
262 Aunradha Rao, Leda Bassit, and Morgan Greenleaf, for the provision of samples with
263 characterized variant strains for assay evaluation.

264

265 **Funding**

266 This work was partially funded by Consejo Nacional de Ciencia y Tecnología with FEEI
267 support, CONACYT, Paraguay; PINV20-239 (MM) and the Doris Duke Charitable Foundation,
268 Clinical Scientist Development Award 2019089478 (JJW)

269

270 **Conflict of Interests**

271 Authors declare that they have no conflict of interest.

272 **References**

- 273 [1] Centers for Disease Control and Prevention, SARS-CoV-2 Variant Classifications and Definitions.
274 <https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html#Concern>, 2021 (accessed 2
275 September 2021.2021).
- 276 [2] J.L. Gardy, N.J. Loman, Towards a genomics-informed, real-time, global pathogen surveillance
277 system, *Nat Rev Genet* 19(1) (2018) 9-20.
- 278 [3] D. Vavrek, L. Speroni, K.J. Curnow, M. Oberholzer, V. Moeder, P.G. Febbo, Genomic surveillance at
279 scale is required to detect newly emerging strains at an early timepoint, *medRxiv* (2021)
280 2021.01.12.21249613.
- 281 [4] Pan American Health Organization, Recommendations for reporting and notification of SARS-CoV-2
282 Variants of Concern and Variants of Interest, 2021.
- 283 [5] World Health Organization, Guidance for surveillance of SARS-CoV-2 variants, 2021.
- 284 [6] P. Banada, R. Green, S. Banik, A. Chopoorian, D. Streck, R. Jones, S. Chakravorty, D. Alland, A
285 Simple RT-PCR Melting temperature Assay to Rapidly Screen for Widely Circulating SARS-CoV-2
286 Variants, *Journal of clinical microbiology* (2021) JCM0084521.
- 287 [7] M. Bedotto, P.E. Fournier, L. Houhamdi, A. Levasseur, J. Delerce, L. Pinault, A. Padane, A.
288 Chamieh, H. Tissot-Dupont, P. Brouqui, C. Sokhna, E. Azar, R. Saile, S. Mboup, I. Bitam, P. Colson, D.
289 Raoult, Implementation of an in-house real-time reverse transcription-PCR assay for the rapid detection
290 of the SARS-CoV-2 Marseille-4 variant, *Journal of clinical virology : the official publication of the Pan*
291 *American Society for Clinical Virology* 139 (2021) 104814.

- 292 [8] L. Blairon, R. Cupaiolo, S. Piteus, I. Beukinga, M. Tre-Hardy, The challenge of screening SARS-
293 CoV-2 variants of concern with RT-qPCR: One variant can hide another, *Journal of virological methods*
294 297 (2021) 114248.
- 295 [9] J.V. Camp, C. Buchta, J. Jovanovic, E. Puchhammer-Stockl, B. Benka, A. Griesmacher, S.W. Aberle,
296 I. Goerzer, RT-PCR based SARS-CoV-2 variant screening assays require careful quality control, *Journal*
297 *of clinical virology : the official publication of the Pan American Society for Clinical Virology* 141
298 (2021) 104905.
- 299 [10] L. Heijnen, G. Elsinga, M. de Graaf, R. Molenkamp, M.P.G. Koopmans, G. Medema, Droplet digital
300 RT-PCR to detect SARS-CoV-2 signature mutations of variants of concern in wastewater, *The Science of*
301 *the total environment* 799 (2021) 149456.
- 302 [11] G. La Rosa, P. Mancini, G. Bonanno Ferraro, C. Veneri, M. Iaconelli, L. Lucentini, L. Bonadonna,
303 S. Brusaferrero, D. Brandtner, A. Fasanella, L. Pace, A. Parisi, D. Galante, E. Suffredini, Rapid screening
304 for SARS-CoV-2 variants of concern in clinical and environmental samples using nested RT-PCR assays
305 targeting key mutations of the spike protein, *Water Res* 197 (2021) 117104.
- 306 [12] D. Norz, M. Grunwald, F. Olearo, N. Fischer, M. Aepfelbacher, S. Pfefferle, M. Lutgehetmann,
307 Evaluation of a fully automated high-throughput SARS-CoV-2 multiplex qPCR assay with built-in
308 screening functionality for del-HV69/70- and N501Y variants such as B.1.1.7, *Journal of clinical virology*
309 *: the official publication of the Pan American Society for Clinical Virology* 141 (2021) 104894.
- 310 [13] S. Tierling, K. Kattler, M. Vogelgesang, T. Pfuhl, S. Lohse, C. Lo Porto, B. Schmitt, S. Nastasja, A.
311 Salhab, S. Smola, J. Walter, Rapid Base-Specific Calling of SARS-CoV-2 Variants of Concern Using
312 Combined RT-PCR Melting Curve Screening and SIRPH Technology, *Open Forum Infect Dis* 8(8)
313 (2021) ofab364.

- 314 [14] N. Vega-Magana, R. Sanchez-Sanchez, J. Hernandez-Bello, A.A. Venancio-Landeros, M. Pena-
315 Rodriguez, R.A. Vega-Zepeda, B. Galindo-Ornelas, M. Diaz-Sanchez, M. Garcia-Chagollan, G. Macedo-
316 Ojeda, O.P. Garcia-Gonzalez, J.F. Munoz-Valle, RT-qPCR Assays for Rapid Detection of the N501Y,
317 69-70del, K417N, and E484K SARS-CoV-2 Mutations: A Screening Strategy to Identify Variants With
318 Clinical Impact, *Front Cell Infect Microbiol* 11 (2021) 672562.
- 319 [15] C.B.F. Vogels, M.I. Breban, I.M. Ott, T. Alpert, M.E. Petrone, A.E. Watkins, C.C. Kalinich, R.
320 Earnest, J.E. Rothman, J. Goes de Jesus, I. Morales Claro, G. Magalhaes Ferreira, M.A.E. Crispim,
321 U.K.C.G.N. Brazil, L. Singh, H. Tegally, U.J. Anyaneji, A. Network for Genomic Surveillance in South,
322 E.B. Hodcroft, C.E. Mason, G. Khullar, J. Metti, J.T. Dudley, M.J. MacKay, M. Nash, J. Wang, C. Liu, P.
323 Hui, S. Murphy, C. Neal, E. Laszlo, M.L. Landry, A. Muyombwe, R. Downing, J. Razeq, T. de Oliveira,
324 N.R. Faria, E.C. Sabino, R.A. Neher, J.R. Fauver, N.D. Grubaugh, Multiplex qPCR discriminates variants
325 of concern to enhance global surveillance of SARS-CoV-2, *PLoS Biol* 19(5) (2021) e3001236.
- 326 [16] H. Wang, S. Jean, R. Eltringham, J. Madison, P. Snyder, H. Tu, D.M. Jones, A.L. Leber, Mutation-
327 Specific SARS-CoV-2 PCR Screen: Rapid and Accurate Detection of Variants of Concern and the
328 Identification of a Newly Emerging Variant with Spike L452R Mutation, *Journal of clinical microbiology*
329 59(8) (2021) e0092621.
- 330 [17] H. Wang, J.A. Miller, M. Verghese, M. Sibai, D. Solis, K.O. Mfuh, B. Jiang, N. Iwai, M. Mar, C.
331 Huang, F. Yamamoto, M.K. Sahoo, J. Zehnder, B.A. Pinsky, Multiplex SARS-CoV-2 Genotyping
332 Reverse Transcriptase PCR for Population-Level Variant Screening and Epidemiologic Surveillance,
333 *Journal of clinical microbiology* 59(8) (2021) e0085921.
- 334 [18] K. Yaniv, E. Ozer, M. Shagan, S. Lakkakula, N. Plotkin, N.S. Bhandarkar, A. Kushmaro, Direct RT-
335 qPCR assay for SARS-CoV-2 variants of concern (Alpha, B.1.1.7 and Beta, B.1.351) detection and
336 quantification in wastewater, *Environ Res* 201 (2021) 111653.

- 337 [19] N. Zelyas, K. Pabbaraju, M.A. Croxen, T. Lynch, E. Buss, S.A. Murphy, S. Shokoples, A. Wong,
338 J.N. Kanji, G. Tipples, Precision Response to the Rise of the SARS-CoV-2 B.1.1.7 Variant of Concern by
339 Combining Novel PCR Assays and Genome Sequencing for Rapid Variant Detection and Surveillance,
340 *Microbiol Spectr* (2021) e0031521.
- 341 [20] A. Babiker, K. Immergluck, S.D. Stampfer, A. Rao, L. Bassit, M. Su, V. Nguyen, V. Stittleburg,
342 J.M. Ingersoll, H.L. Bradley, M. Mavigner, N. Schoof, C.S. Kraft, A. Chahroudi, R.F. Schinazi, G.S.
343 Martin, A. Piantadosi, W.A. Lam, J.J. Waggoner, Single-amplicon, multiplex real-time RT-PCR with
344 tiled probes to detect SARS-CoV-2 spike mutations associated with variants of concern, *Journal of*
345 *clinical microbiology* (2021) JCM0144621.
- 346 [21] Ministerio de Salud Pública y Bienestar Social, Primer caso del nuevo coronavirus en el Paraguay.
347 <https://www.mspbs.gov.py/portal/20535/primer-caso-del-nuevo-coronavirus-en-el-paraguay.html>,
348 2020 (accessed 01 September 2021.).
- 349 [22] Ministerio de Salud Pública y Bienestar Social, <https://www.mspbs.gov.py/index.php>, 2021
350 (accessed 25 August 2021.).
- 351 [23] P. Sobarzo, J.C. Rolón López, P.F. Narváez Serra, S.A. López Cañete, Clinical characteristics of the
352 first 60 patients with SARS CoV-2 admitted to the National Hospital for the period June-August 2020,
353 *Rev. virtual Soc. Parag. Med. Int.* 8(1) (2021) 69-77.
- 354 [24] A. Vargas-Correa, E.F. Mereles, C.N. Segovia, A.A. Gimenez, L. Santacruz, M.L. Ojeda, E.H.
355 Kunzle, M. Samudio, Clinical-epidemiological characteristics of patients confirmed with COVID-19 from
356 the Department of Alto Paraná, Paraguay, *Rev. Salud Pública Parag.* 11(1) (2021) 54-61.
- 357 [25] A. Brinkmann, S.L. Ulm, S. Uddin, S. Forster, D. Seifert, R. Oehme, M. Certy, L. Schaade, J.
358 Michel, A. Nitsche, AmpliCoV: Rapid Whole-Genome Sequencing Using Multiplex PCR Amplification

- 359 and Real-Time Oxford Nanopore MinION Sequencing Enables Rapid Variant Identification of SARS-
360 CoV-2, *Front Microbiol* 12 (2021) 651151.
- 361 [26] V.M. Corman, O. Landt, M. Kaiser, R. Molenkamp, A. Meijer, D.K.W. Chu, T. Bleicker, S.
362 Brunink, J. Schneider, M.L. Schmidt, D. Mulders, B.L. Haagmans, B. van der Veer, S. van den Brink, L.
363 Wijsman, G. Goderski, J.L. Romette, J. Ellis, M. Zambon, M. Peiris, H. Goossens, C. Reusken, M.P.G.
364 Koopmans, C. Drosten, Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR, *Euro*
365 *surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease*
366 *bulletin* 25(3) (2020).
- 367 [27] J.J. Waggoner, V. Stittleburg, R. Pond, Y. Saklawi, M.K. Sahoo, A. Babiker, L. Hussaini, C.S. Kraft,
368 B.A. Pinsky, E.J. Anderson, N. Roupheal, Triplex Real-Time RT-PCR for Severe Acute Respiratory
369 Syndrome Coronavirus 2, *Emerging infectious diseases* 26(7) (2020) 1633-1635.
- 370 [28] J. Quick, nCoV-2019 sequencing protocol v3 (LoCost) V.3. <[https://www.protocols.io/view/ncov-](https://www.protocols.io/view/ncov-2019-sequencing-protocol-v3-locost-bh42j8ye)
371 [2019-sequencing-protocol-v3-locost-bh42j8ye](https://www.protocols.io/view/ncov-2019-sequencing-protocol-v3-locost-bh42j8ye)>, 2020).
- 372 [29] J. Hadfield, C. Megill, S.M. Bell, J. Huddleston, B. Potter, C. Callender, P. Sagulenko, T. Bedford,
373 R.A. Neher, Nextstrain: real-time tracking of pathogen evolution, *Bioinformatics* 34(23) (2018) 4121-
374 4123.
- 375 [30] A. Rambaut, E.C. Holmes, A. O'Toole, V. Hill, J.T. McCrone, C. Ruis, L. du Plessis, O.G. Pybus, A
376 dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology, *Nat*
377 *Microbiol* 5(11) (2020) 1403-1407.
- 378 [31] N.R. Faria, T.A. Mellan, C. Whittaker, I.M. Claro, D.D.S. Candido, S. Mishra, M.A.E. Crispim,
379 F.C.S. Sales, I. Hawryluk, J.T. McCrone, R.J.G. Hulswit, L.A.M. Franco, M.S. Ramundo, J.G. de Jesus,
380 P.S. Andrade, T.M. Coletti, G.M. Ferreira, C.A.M. Silva, E.R. Manuli, R.H.M. Pereira, P.S. Peixoto,
381 M.U.G. Kraemer, N. Gaburo, Jr., C.D.C. Camilo, H. Hoeltgebaum, W.M. Souza, E.C. Rocha, L.M. de

- 382 Souza, M.C. de Pinho, L.J.T. Araujo, F.S.V. Malta, A.B. de Lima, J.D.P. Silva, D.A.G. Zauli, A.C.S.
383 Ferreira, R.P. Schnekenberg, D.J. Laydon, P.G.T. Walker, H.M. Schluter, A.L.P. Dos Santos, M.S. Vidal,
384 V.S. Del Caro, R.M.F. Filho, H.M. Dos Santos, R.S. Aguiar, J.L. Proenca-Modena, B. Nelson, J.A. Hay,
385 M. Monod, X. Miscouridou, H. Coupland, R. Sonabend, M. Vollmer, A. Gandy, C.A. Prete, Jr., V.H.
386 Nascimento, M.A. Suchard, T.A. Bowden, S.L.K. Pond, C.H. Wu, O. Ratmann, N.M. Ferguson, C. Dye,
387 N.J. Loman, P. Lemey, A. Rambaut, N.A. Fraiji, M. Carvalho, O.G. Pybus, S. Flaxman, S. Bhatt, E.C.
388 Sabino, Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil, *Science*
389 372(6544) (2021) 815-821.
- 390 [32] F.G. Naveca, V. Nascimento, V.C. de Souza, A.L. Corado, F. Nascimento, G. Silva, A. Costa, D.
391 Duarte, K. Pessoa, M. Mejia, M.J. Brandao, M. Jesus, L. Goncalves, C.F. da Costa, V. Sampaio, D.
392 Barros, M. Silva, T. Mattos, G. Pontes, L. Abdalla, J.H. Santos, I. Arantes, F.Z. Dezordi, M.M. Siqueira,
393 G.L. Wallau, P.C. Resende, E. Delatorre, T. Graf, G. Bello, COVID-19 in Amazonas, Brazil, was driven
394 by the persistence of endemic lineages and P.1 emergence, *Nature medicine* 27(7) (2021) 1230-1238.
- 395 [33] J. Singh, S.A. Rahman, N.Z. Ehtesham, S. Hira, S.E. Hasnain, SARS-CoV-2 variants of concern are
396 emerging in India, *Nature medicine* 27(7) (2021) 1131-1133.
- 397 [34] Z. Liu, L.A. VanBlargan, L.M. Bloyet, P.W. Rothlauf, R.E. Chen, S. Stumpf, H. Zhao, J.M. Errico,
398 E.S. Theel, M.J. Liebeskind, B. Alford, W.J. Buchser, A.H. Ellebedy, D.H. Fremont, M.S. Diamond,
399 S.P.J. Whelan, Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum
400 antibody neutralization, *Cell Host Microbe* 29(3) (2021) 477-488 e4.
- 401 [35] R.D.S. Francisco, Jr., L.F. Benites, A.P. Lamarca, L.G.P. de Almeida, A.W. Hansen, J.S. Gularte, M.
402 Demoliner, A.L. Gerber, C.G.A.P. de, A.K.E. Antunes, F.H. Heldt, L. Mallmann, B. Hermann, A.L.
403 Ziulkoski, V. Goes, K. Schallenberger, M. Fillipi, F. Pereira, M.N. Weber, P.R. de Almeida, J.D. Fleck,
404 A.T.R. Vasconcelos, F.R. Spilki, Pervasive transmission of E484K and emergence of VUI-NP13L with

405 evidence of SARS-CoV-2 co-infection events by two different lineages in Rio Grande do Sul, Brazil,
406 *Virus Res* 296 (2021) 198345.

407 [36] K.A. Lythgoe, M. Hall, L. Ferretti, M. de Cesare, G. MacIntyre-Cockett, A. Trebes, M. Andersson,
408 N. Otecko, E.L. Wise, N. Moore, J. Lynch, S. Kidd, N. Cortes, M. Mori, R. Williams, G. Vernet, A.
409 Justice, A. Green, S.M. Nicholls, M.A. Ansari, L. Abeler-Dorner, C.E. Moore, T.E.A. Peto, D.W. Eyre,
410 R. Shaw, P. Simmonds, D. Buck, J.A. Todd, G. Oxford Virus Sequencing Analysis, T.R. Connor, S.
411 Ashraf, A. da Silva Filipe, J. Shepherd, E.C. Thomson, C.-G.U. Consortium, D. Bonsall, C. Fraser, T.
412 Golubchik, SARS-CoV-2 within-host diversity and transmission, *Science* 372(6539) (2021).

413

414 **Figure Legends**

415 **Figure 1.** Graphical display of the 348-base-pair Spike SNP target including the nucleic acid
416 sequence and amino acid translation of the Wuhan-Hu-1 strain (NC_045512.2). The locations of
417 the forward and reverse primer sequences and all hydrolysis probes are shown. Probe colors
418 correspond to fluorophores on each probe and the detection channel in the Rotor-Gene Q
419 instrument. Detected nucleotide changes are displayed within the probe, and amino acid
420 mutations are shown below the sequence. The probe for K417 is marked (*) as this is the only
421 probe for which variant sequences result in signal loss and this has only been successfully
422 designed with LNA bases.

423

424 **Figure 2. Addition of 478K probe does not impact signal from 452Q or 490S probes.**

425 Amplification curves are shown for 100-fold dilutions of C.37 (lambda) and B.1.617.2 (delta)
426 samples tested together on a single run. Results were similar for **A**) 452Q and **C**) 490S mutations
427 in C.37 with the probe for 478K (solid curves) or without (dotted curves). Results for B.1.617.2
428 were similar with the 478K probe (**B**) used in singleplex (dotted curves) or triplex reactions
429 (solid curves). Nonspecific signals were not detected in any channel.

430

431 **Figure 3. Distribution of N2 Ct values for A) all samples and B) the four most common**

432 **genotypes detected.** A) N2 Ct values for all tested samples are displayed. Three samples that
433 tested negative in the Spike SNP assay are highlighted (dark triangles) and had N2 Ct values of
434 32.6, 36.6, and 35.1. B) N2 Ct values for the four most common genotypes detected. Bars
435 represent mean Ct and standard deviation, and p-values for tested comparisons are displayed
436 above the graph.

437

438 **Figure 4. Spike SNP and amplicon sequencing results are concordant.** Amplification curves
439 and amplicon sequence tracings are shown for samples with mutations encoding **A**) 484K and
440 501Y (purple curves) or **B**) 484K only with N501 (cranberry). A beta variant control sample is
441 shown for reference (blue curves).

442 **Table 1.** Spike SNP assay primers and probes used in the current study.

Name	Sequence ^a	Concentration	Location
		(nM) ^b	(5'-3') ^c
<i>Primers</i>			
SpikeSNP Ext ^d	TGAAGTCAGACAAATCGCTCC	400	22777-22797
SpikeSNP R1 ^d	TGGTGCATGTAGAAGTTCAAAAG	400	23103-23125
<i>LNA Probes</i>			
K417 ^d	5'-FAM-CAAACCTGGA+A+ <u>A</u> + <u>G</u> +ATTGCTG-3IABkFQ-3'	200	22802-22820
484K ^d	5'-Cy5-ACCTTGTAATGGTGT+T+ <u>A</u> +AAGGTTTT-3IAbRQSp-3'	200	22996-23020
501Y ^d	5'-HEX-CCCAC+T+ <u>T</u> +ATGGTGTTGG-3IABkFQ-3'	200	23057-23073
<i>Unmodified Probes</i>			
452R ^d	5'-CFR610-ATAATTACCGGTATAGATTGTTTAGGAAGT-BHQ-2-3'	200	22908-22937
484K	5'-Q670-CACCTTGTAATGGTGTT <u>A</u> AAGGTTTTAA-BHQ-2-3'	200	22995-23022
484Q	5'-Q670-CACCTTGTAATGGTGTT <u>C</u> AAGGTTTTAA-BHQ-2-3'	200	22995-23022
501Y	5'-CFO560-CAACCCACT <u>T</u> ATGGTGTTGGTTAC-BHQ-1-3'	200	23054-23077
452Q	5'-CFR610-ATAATTACCA <u>G</u> TATAGATTGTTTAGGAAGT-BHQ-2-3'	200	22908-22937
490S	5'-FAM-ACT <u>C</u> TCCTTTACAATCATATGGTTTCC-BHQ-1-3'	200	23028-23054
478K	5'-CFO560-CGGTAGCA <u>A</u> ACCTTGTAATGGTG-BHQ-1-3'	200	22987-23009

443 Abbreviations: BHQ, black hole quencher; CFO560, CAL Fluor Orange 560; CFR610, CAL Fluor Red 610; Cy5,

444 Cyanine 5; FAM, Fluorescein; IABkFQ/IAbRQSp, Iowa Black quenchers; Q670, Quasar 670

445 ^a probe sequences listed 5'-fluorophore-sequence-quencher-3'; "+" before base indicates a locked nucleic acid, bold

446 and underlined base indicates the targeted single nucleotide change

447 ^b Concentration in the final reaction mixture

448 ^c Location in Wuhan-Hu-1 complete genome sequence (NCBI Reference Sequence: NC_045512.2)

449 ^d Previously published, presented for clarity

450 **Table 2.** Genotypes detected in the Spike SNP assay, patient demographics and the percent
 451 confirmed by amplicon sequencing.

Category	n (%)	Age, years,	Day of Symptoms,	Ct, mean (SD) ^c	Sequencing
		mean (SD) ^a	Mean (SD) ^b		Confirmed, n/N (%) ^d
N2 detected	201 (100)	42.6 (16.4)	4.8 (3.0)	20.8 (5.6)	—
Spike SNP detected	198 (98.5)	42.5 (16.4)	4.8 (3.0)	20.6 (5.3)	181/181 (100)
<i>Genotype^e</i>					
417var/484K/501Y	102 (51.5)	42.8 (14.9)	4.5 (2.4)	19.3 (5.0)	96/96 (100)
K417	64 (32.3)	42.6 (18.8)	5.1 (3.7)	22.1 (5.4)	56/56 (100)
K417/484K	22 (11.1)	37.4 (14.2)	4.8 (2.7)	22.2 (5.4)	20/20 (100) ^f
K417/452R	7 (3.5)	54.0 (15.8)	5.0 (4.6)	19.4 (4.0)	7/7 (100)
K417/490S	1 (0.5)	41	4	15.2	1/1 (100)
K417/501Y	1 (0.5)	68	5	19.7	1/1 (100)
K417/484K/501Y	1 (0.5)	19	10	32.1	NA

452 Abbreviations: var, variant; SD, standard deviation

453 ^a Age available for 194/201 (96.5%) samples

454 ^b Day of symptoms available for 136/201 (67.7%) samples

455 ^c Ct value in the N2 assay

456 ^d Number with sequence confirmed (n) over the number of amplicons with high quality sequence and base calls at
 457 each SNP position (N)

458 ^e Displayed as % of Spike SNP positive samples

459 ^f One sample had a mixed base (A/G) at the position targeted by the 484K probe

460 **Table 3.** Spike mutations and identified lineages by genome sequencing.

Sample Code	Spike SNP Genotype	Nanopore Sequencing			
		GISAID Accession No.	Nextstrain Clade WHO label	Pango Lineage	Spike deletions /amino acid substitutions ^a
PY21-100	417var/484K/501Y	EPI_ISL_4071892	20J (V3) gamma	P.1	L18F/T20N/P26S/D138Y/R190S/ K417T/E484K/N501Y /D614G/ H655Y/T1027I/ V1176F
PY21-9	417var/484K/501Y	EPI_ISL_2444778	20J (V3) gamma	P.1	L18F//T20N/P26S/D138Y/R190S/ K417T/E484K/N501Y /D614G/ H655Y/T1027I/V1176F
PY21-57	417var/484K/501Y	EPI_ISL_4137476	20J (V3) gamma	P.1	L18F/T20N/P26S/D138Y/R190S/ K417T/E484K/N501Y /D614G/ H655Y/T1027I/V1176F
PY21-58	417var/484K/501Y	EPI_ISL_4071897	20J (V3) gamma	P.1	L18F/T20N/P26S/D138Y/R190S/ K417T/E484K/N501Y /D614G/ H655Y/T1027I/V1176F
PY21-84	417var/484K/501Y	EPI_ISL_4071898	20J (V3) gamma	P.1	L18F/T20N/P26S/D138Y/R190S/ K417T/E484K/N501Y /D614G/ H655Y/T1027I/V1176F
PY21-16	417var/484K/501Y	EPI_ISL_4071893	20J (V3) gamma	P.1	L18F/T20N/P26S/D138Y/R190S/ K417T/E484K/N501Y /D614G/ H655Y/T1027I/V1176F
PY21-11	417var/484K/501Y	EPI_ISL_4071900	20J (V3) gamma	P.1	L18F/T20N/P26S/D138Y/L189F/R190S/ K417T/E484K/ N501Y / D614G/H655Y/T1027I/V1176F
PY21-90	417var/484K/501Y	EPI_ISL_4071899	20J (V3) gamma	P.1.2	L18F/T20N/P26S/T95I/D138Y/R190S/ K417T/E484K/N501Y /D614G/H655Y/ Q675H/T1027I/V1176F/V1228L
PY21-150	K417	EPI_ISL_2234899	20B	B.1.1.33	D614G
PY21-153	K417	EPI_ISL_2234891	20B	B.1.1.33	D614G
PY21-140	K417	EPI_ISL_2234880	20B	B.1.1.28	D614G/V1176F
PY21-145	K417	EPI_ISL_4084605	20B	B.1.1.28	D614G/V1176F
PY21-146	K417	EPI_ISL_2234881	20B	B.1.1.28	D614G/V1176F
PY21-98	K417	EPI_ISL_2444788	20B	B.1.1.28	D614G/V1176F
PY21-152	K417	EPI_ISL_2234885	20B	B.1.1.28	T22I/D614G/V1176F
PY21-144	K417	EPI_ISL_4071901	20B	B.1.1.28	D614G/N1135Y/V1176F
PY21-43	K417	EPI_ISL_4071895	20B	B.1.1.28	A575S/D614G/V1176F
PY21-44	K417	EPI_ISL_4084604	20B	B.1.1.28	T572I/D614G/V1176F
PY21-47	K417	EPI_ISL_4071894	20B	B.1.1.28	A575S/D614G/V1176F
PY21-148	K417	EPI_ISL_2234894	20B	B.1.1.28	V6F/L18F/D614G/V1176F
PY21-147	K417	EPI_ISL_2234887	20B	B.1.1.28	Q14H/D614G/D1153A/V1176F
PY21-154	K417	EPI_ISL_2234893	20B	B.1.1.277	D614G/V1176F
PY21-52	K417/484K	EPI_ISL_2444780	20B (zeta)	P.2	E484K /D614G/V1176F
PY21-157	K417/484K	EPI_ISL_2234879	20B (zeta)	P.2	L5F/ E484K /D614G/A771S/V1176F
PY21-143	K417	EPI_ISL_2234889	20B	N.3	T76I/D614G
PY21-141	K417	EPI_ISL_2234883	20C	B.1.499	T478R/D614G
PY21-149	K417	EPI_ISL_2234897	20C	B.1.499	T478R/D614G
PY21-102	K417/452R	EPI_ISL_4071896	19B	A.2.5.2	L452R /D614G
PY21-156	K417/501Y	EPI_ISL_4084606	20I (V1) alpha	B.1.1.7	DEL69-70/DEL144 N501Y /A570D/D614G/P681H/T716I/S982A/ D1118H

461 Abbreviations: var, variant; WHO, World Health Organization

462 ^a Bold text indicates amino acid substitutions detected by the Spike SNP assay.

Figure 1

SpikeSNP Ext



K417*

A

G

452Q

452R



SpikeSNP R1



A

C

A

C

T

478K

484K

484Q

490S

501Y

Figure 2






Figure 3







Figure 4

A



B

